As a credible, global insulins player, Biocon made sure-footed progress towards its mission of providing a high quality, affordable insulin analog for people with diabetes globally when the European Commission approved the biosimilar Insulin Glargine application submitted by its co-development partner Mylan.
Biocon and Mylan are among the first few to receive approval for biosimilar Insulin Glargine in Europe. Semglee™ (Insulin Glargine) is the first biosimilar from Biocon and Mylan’s joint portfolio to be approved in Europe.
Biocon embarked upon the Insulin Glargine development journey after successful launch of Insugen® (recombinant human Insulin) in India.
Insulin Glargine is a long-acting insulin analog that offers better glucose control with the convenience of once daily injection versus the discomfort of multiple daily injections and reduces the possibility of developing hypoglycemia (low blood sugar). It is prescribed for adults with Type 2 diabetes as well as adults and pediatric patients (children 2 years and older) with Type 1 diabetes.
The biological process of manufacturing Insulin Glargine starts with a yeast cell, Pichia pastoris, which is genetically engineered to express the human Insulin Glargine protein, when grown in culture, which is then purified and formulated. The quality of the Insulin Glargine is established and controlled using multiple orthogonal analytical techniques.
The CMC development, non-clinical and clinical studies for Insulin Glargine in India culminated in its approval and subsequent launch under the brand name BASALOG® in 2009.
Biocon’s global CMC development program was aimed at taking Insulin Glargine to people with diabetes worldwide. Our comparative pharmacokinetics / pharmacodynamics (PK/PD), Phase I trials demonstrated the bioequivalence of biosimilar Insulin Glargine with the reference product in glucose clamp studies.
Type: Long-acting insulin analog
Indications: Control of high blood sugar in adults with Type 2 diabetes; adults and pediatric patients with Type 1 diabetes.
Global Sales: USD 5.2 billion*
(*Innovator Sales, Source: Company reports)
In 2013, we expanded an existing global partnership with U.S.-based Mylan to include insulin analogs, Glargine, Aspart and Lispro. Subsequently, we initiated the global INSTRIDE clinical program to establish the efficacy, safety and immunogenicity of biosimilar Insulin Glargine in comparison to the reference product in patients with Type 1 and Type 2 diabetes.
INSTRIDE 1 was a 52-week study in 558 Type 1 diabetes patients, while INSTRIDE 2 was a 24-week study in 560 Type 2 diabetes patients. In both the studies, patients were randomized to receive either biosimilar Insulin Glargine or the reference product once daily and the primary endpoint was change from baseline in HbA1c after 24 weeks. Secondary endpoints included glycemic endpoints such as change from baseline in fasting plasma glucose and insulin dose, as well as, safety endpoints like systemic reactions, device-related safety issues and immunogenicity.
On conclusion of the trials, we made a regulatory submission with the European Medicines Agency (EMA) in 2016 through our partner Mylan, which included analytical, functional and pre-clinical data, as well as results from the PK/PD and confirmatory efficacy/safety global clinical trials for biosimilar Insulin Glargine.
In 2015, our product became the first Insulin Glargine to be approved in Mexico as per the country’s biologics approval pathway.
Approvals Across the Globe
Subsequently, we achieved a major regulatory milestone with approval of our Insulin Glargine in Japan. The approval followed the successful completion of initial development by Biocon and local comparative Phase I followed by Phase III clinical studies in over 250 Type 1 diabetes patients by our Japanese partner. This was Biocon’s first biosimilar approval in a developed market and the first biosimilar from a company in India approved in Japan. The approval and launch of our Insulin Glargine disposable pen in Japan in 2016 was an important continuing endorsement of our product quality.
Biocon’s innovative, pre-filled pen Insulin Glargine pen was launched in 2015 as Basalog One™ in India, where it continues to make a significant difference to diabetes patients on insulin therapy.
Till date, 1,700 patients and healthy volunteers have been evaluated in comparative clinical studies conducted across the U.S., EU, Japan, India, Canada and other countries for establishing the safety and efficacy of Biocon’s Insulin Glargine.
In January 2018, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended Insulin Glargine co-developed by Biocon and Mylan for approval. After CHMP’s positive opinion, the European Commission approved the sale of the biosimilar Insulin Glargine, Semglee™ 100 units/mL 3 mL prefilled disposable pen, in March 2018.
Semglee™ 100 units/mL 3 mL prefilled disposable pen, our biosimilar Insulin Glargine was approved by the European Commission for sale in all 28 European Union (EU) member states and the European Economic Area (EEA) member states of norway, Iceland and Liechtenstein.
Semglee™ 100 IU/mL 3 mL prefilled pen was also approved by the Therapeutic Goods Administration (TGA), Australia.
In the U.S., Mylan’s application for Insulin Glargine under the NDA pathway is under review by the U.S. FDA
Biocon’s biosimilar Insulin Glargine has also been approved in Russia, Mexico, South Korea, Malaysia and 28 other countries, enabling us to provide an affordable treatment option to millions of people with diabetes worldwide.